and/or patients with a high metabolic burden who have already entered the fertility pathway but encountered metabolic-related barriers during ART (e.g., high OHSS risk, suboptimal oocyte/embryo quality, or cycle cancelation)
On December 10, 2024, the FDA issued a warning letter to Prime Vitality, Inc
Despite the success of anti-CD20 monoclonal antibodies in cancer treatment, there are also several cancers associated with the use of anti-B cell therapies
Additionally, palmitate treatment upregulated the expression of PPAR-, CD36, and proteins associated with inflammasome complex formation (NLRP3, ASC, caspase-1, and IL-1)
Goldberg DT, Yaskolka Meir A, Tsaban G, Rinott E, Kaplan A, Zelicha H, Kloting N, Ceglarek U, Iserman B, Shelef I, Rosen P, Bluher M, Stumvoll M, Etzion O, Stampfer MJ, Hu FB, Shai I (2024) Novel proteomic signatures may indicate MRI-assessed intrahepatic fat state and changes: the DIRECT PLUS clinical trial